Related Experiment Videos
Lipids in women: screening and treatment
1Division of General Internal Medicine, Department of Medicine, University of California, San Francisco 94115, USA. Jwalsh@medicine.ucsf.edu
Insights
Hyperlipidemia increases coronary heart disease (CHD) risk in women, but research often excluded them. This article provides screening and treatment guidelines specifically for women
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Preventive Cardiology
Background:
- Hyperlipidemia is a significant risk factor for coronary heart disease (CHD).
- Existing research on lipid-lowering therapies has historically underrepresented women or analyzed their data separately.
- Differences in cholesterol's impact on CHD risk exist between men and women.
Purpose of the Study:
- To address the gap in evidence regarding hyperlipidemia management in women.
- To provide specific guidelines for screening and treating hyperlipidemia in various female populations.
- To improve CHD risk assessment and decision-making for women.
Main Methods:
- Review of existing clinical trials and epidemiological data on hyperlipidemia and CHD in women.
- Analysis of sex-specific differences in lipid profiles and cardiovascular risk.
- Development of evidence-based recommendations for screening and treatment strategies.
Main Results:
- The association between cholesterol levels (total, LDL, HDL) and CHD risk varies between men and women.
- Women have been inadequately represented in major lipid-lowering clinical trials.
- Separate analysis of women's data is crucial for understanding treatment efficacy and safety.
Conclusions:
- Tailored guidelines are necessary for effective hyperlipidemia screening and treatment in women.
- Addressing underrepresentation in research is vital for advancing women's cardiovascular health.
- Proactive CHD risk assessment and management are essential for all women, particularly those with or at risk for hyperlipidemia.
Abstract:
Hyperlipidemia is a risk factor for coronary heart disease (CHD) in both men and women, although the association between total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and CHD risk differs in men and women. Although several clinical trials of lipid lowering for both primary and secondary prevention of CHD have been conducted, women have not always been included, have been included in small numbers, or have not had their results analyzed separately. CHD risk assessment is an important component of decision making about screening and treatment of hyperlipidemia. This article presents guidelines for screening and treatment of hyperlipidemia in women with CHD, in healthy women, and in women at risk for CHD.